Indian pharma industry should strive to maintain the reputation of India as the ‘Pharmacy of the World’: Dr Mansukh Mandaviya

“The Indian pharma industry should strive to maintain the reputation of India as the ‘Pharmacy of the World’ which was established during the Covid-19 crisis” said Union Minister for Chemicals & Fertilizers and Health & Family Welfare, Dr Mansukh Mandaviya at the closing ceremony of IPA’s 8th Global Pharmaceutical Quality Summit.

“The country could achieve this feat with the shared responsibility of the Government and pharma industry during the global crisis. The industry relentlessly worked to follow all instructions given by the Government, knowing the huge responsibility on them and made all the medicines required for treatment of Covid-19 available. They also supported the Government to produce the various vaccines”, added Shri. Mandviya.

While lauding the responsible approach of the industry he said that nobody ever thought of their own profit or became selfish and took undue advantage of the situation. Due to this support and the responsible approach, India could supply necessary medicines and vaccines to more than 150 countries. At the same time the Minister also pointed towards the importance of the quality of the medicines. He said that no country complained about the quality of the medicines as the Indian pharma industry never compromises with the quality of the medicines. We know that like all the other sectors there are few people who try to compromise with the quality of the products. But they should always remember that the government has zero tolerance policy against these element. He further informed that Government is taking stringent actions against the companies involved in such type of malpractices. He urged the pharma industry to establish a self regulatory body to monitor the quality of  pharma products. He also added that the country is marching ahead in the field of research and innovation as the government has opened its research facilities to all including the private sector.

Addressing the gathering on the occasion, Shri. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance, said, “The Indian pharmaceutical industry plays a critical role in shaping the health outcomes of patients globally. India is known for providing quality-assured affordable medicines worldwide. During the COVID-19 pandemic, the industry demonstrated resilience and is now known as the pharmacy of the world. Quality is the fundamental tenet of the pharmaceutical sector. Continuous investments in quality –systems, technology and talent – is fundamental as the overall healthcare landscape is evolving at an unprecedented pace. IPA is committed to making India a global benchmark in quality.”

The theme for the 8th edition of the Global Pharmaceutical Quality Summit was, ‘Patient Centricity: New Paradigm of Manufacturing and Quality’. The two-day Summit brought together industry leaders, global regulators, quality experts and stakeholders to foster knowledge exchange and deliberate on areas of importance in shaping the pharmaceutical landscape in India.

The event was inaugurated by Mr Samir Mehta, Chairman, Torrent Pharmaceuticals and President, IPA. Ms S Aparna, Secretary, Department of Pharmaceuticals, Government of India, delivered the keynote address during the inaugural session. The first day highlighted the importance of the future of manufacturing and building quality as a culture in the pharmaceutical industry. Regulators from around the world - US FDA, MHRA, EDQM and CDSCO discussed the regulatory affairs highlighting recent inspection observations and trends. The day concluded with discussions on technology architecture, exploring best-in-class engineering controls to ensure excellence in pharmaceutical production.

Day two of the summit witnessed industry leaders shedding light on industry advancements, continuous manufacturing, regulatory expectation, digital technologies in pharmaceutical manufacturing and learnings from other industries. The highlight of the day was the panel discussion comprising leading CEOs of the pharma industry from Cipla, Dr Reddy’s, Lupin, Sun Pharma and Zydus providing their thoughts on the future of the Indian pharmaceutical industry.

About IPA:

Indian Pharmaceutical Alliance represents 24 research-based national pharmaceutical companies. Collectively, IPA companies account for over 85 percent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country’s exports of drugs and pharmaceuticals and service over 60 per cent of the domestic market. For more information, visit